Cullinan Seeks Approval for EGFR Inhibitor in NSCLC

Cullinan Therapeutics has submitted a New Drug Application to the US FDA seeking approval for zipalertinib, an EGFR inhibitor, combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer with EGFR exon 20 insertions.

This Wire brief sits within Fusion42's coverage of Biotech.